Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Cushing's Disease in Older Patients

Published: Mon, 19 Nov 2018 12:00:00 EST
The clinical presentation and outcomes of older patients with Cushing's disease may differ from that of younger patients. Find out what there is to know.
Clinical Endocrinology

Dual Therapy With Raltegravir and a bPI in Pretreated HIV

Published: Mon, 19 Nov 2018 12:00:00 EST
Might treatment with raltegravir-containing combinations provide a feasible option for HIV patients who have failed previous therapies?
HIV Medicine

TB Treatment Monitoring by Video Directly Observed Therapy

Published: Mon, 19 Nov 2018 12:00:00 EST
Is this video-based approach a feasible means of assessing tuberculosis treatment adherence?
Emerging Infectious Diseases

Targeted Therapy to Resensitize Tumors to Radioactive Iodine

Published: Mon, 19 Nov 2018 12:00:00 EST
How might targeted therapy help patients with advanced thyroid cancer that has become radioactive iodine refractory?
Journal of Clinical Endocrinology & Metabolism
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


New insight into why malaria drugs work against some cancers could boost drug development

Published: Fri, 16 Nov 2018 14:58:13 +0000
Researchers at Penn’s Abramson Cancer Center discovered that antimalarial drugs known as chloroquines play a role in inhibiting cancer cell growth by targeting the enzyme PPT1. They've launched a startup, Pinpoint Therapeutics, to translate their discoveries into new cancer therapies.

MorphoSys partners anti-C5aR I-O antibody with I-Mab

Published: Fri, 16 Nov 2018 13:24:08 +0000
MorphoSys has partnered with I-Mab to support development of anti-C5aR antibody MOR210. The deal sees I-Mab agree to take the immuno-oncology candidate up to clinical proof of concept.

Lori Kunkel takes acting CMO role at gene therapy firm Tocagen

Published: Fri, 16 Nov 2018 13:07:34 +0000
Tocagen has named Lori Kunkel as its acting chief medical officer following the departure of Asha Das, who is leaving because of “unforeseen and immediate personal matters.”

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

Published: Fri, 16 Nov 2018 10:51:54 +0000
Overall survival data from AstraZeneca’s phase 3 Mystic trial have cast more doubts on the prospects of anti-CTLA4 antibody tremelimumab. The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic non-small cell lung cancer (NSCLC).
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy